Etidronate’s primary site of action is bone. It reduces normal and abnormal bone resorption. This effect can reduce hypercalcemia associated with malignant neoplasms. Etidronate can also increase serum phosphate concentrations, presumably by increasing the renal tubular reabsorption of phosphate. Some early studies in lab animals suggest that etidronate may inhibit the formation of bone metastases with some tumor types.
Etodolac is labeled for the management of pain and inflammation associated with osteoarthritis in dogs. It may find uses, however, for a variety of conditions where pain and/or inflammation should be treated.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
任何考量都必須由獸醫師另行核對確切鹽型與成品、動物種類、病因與嚴重度、骨骼與腎臟狀況、礦物平衡、其他用藥及所在地法規；本筆不提供可執行數值。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。